These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29429550)

  • 21. Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
    Papadakis V; Karakasis D; Sfikakis PP; Baltadakis I; Apostolidis J; Evangelou K; Gorgoulis VG; Harhalakis N
    Leuk Lymphoma; 2009 Mar; 50(3):471-4. PubMed ID: 19253137
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
    Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
    Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
    Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
    Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
    [No Abstract]   [Full Text] [Related]  

  • 24. Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.
    Rosenthal EA; Ho PS; Joe GO; Mitchell SA; Booher S; Pavletic SZ; Baird K; Cowen EW; Comis LE
    Support Care Cancer; 2020 Aug; 28(8):3679-3689. PubMed ID: 31811481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A call for more dermatologic input into chronic graft-vs-host disease clinical trials.
    Cowen EW
    Arch Dermatol; 2009 Mar; 145(3):337-8. PubMed ID: 19289778
    [No Abstract]   [Full Text] [Related]  

  • 26. Firm advances in sclerodermatous disorders.
    Heymann WR
    J Am Acad Dermatol; 2023 Jan; 88(1):27-28. PubMed ID: 36403752
    [No Abstract]   [Full Text] [Related]  

  • 27. CT and MRI findings in sclerodermatous chronic graft vs. host disease.
    Dumford K; Anderson JC
    Clin Imaging; 2001; 25(2):138-40. PubMed ID: 11483427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PUVA treatment in sclerodermatoid spectrum of dermatologic diseases: our initial experience.
    Baum S; Pavlotsky F; Shpiro D; Trau H
    Isr Med Assoc J; 2004 Sep; 6(9):563-4. PubMed ID: 15373320
    [No Abstract]   [Full Text] [Related]  

  • 29. Bullous scleroderma-like changes in chronic graft-versus-host disease.
    Moreno JC; Valverde F; Martinez F; Vélez A; Torres A; Fanego J; Ocaña MS
    J Eur Acad Dermatol Venereol; 2003 Mar; 17(2):200-3. PubMed ID: 12705752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children.
    Faraci M; Ricci E; Bagnasco F; Pierri F; Giardino S; Girosi D; Olcese R; Castagnola E; Michele Magnano G; Lanino E
    Pediatr Pulmonol; 2020 Mar; 55(3):631-637. PubMed ID: 31951682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.
    Morin F; Kavian N; Marut W; Chéreau C; Cerles O; Grange P; Weill B; Nicco C; Batteux F
    J Invest Dermatol; 2015 Oct; 135(10):2385-2393. PubMed ID: 25938558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib treatment of generalized localized scleroderma (morphea).
    Moinzadeh P; Krieg T; Hunzelmann N
    J Am Acad Dermatol; 2010 Nov; 63(5):e102-4. PubMed ID: 20950732
    [No Abstract]   [Full Text] [Related]  

  • 33. Macroscopic and microscopic mucinosis in chronic sclerodermoid graft-versus-host disease.
    Ameen M; Russell-Jones R
    Br J Dermatol; 2000 Mar; 142(3):529-32. PubMed ID: 10735965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. October 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
    Nusbaum AG; Miteva M
    J Invest Dermatol; 2015 Oct; 135(10):e33. PubMed ID: 26358389
    [No Abstract]   [Full Text] [Related]  

  • 35. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
    Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
    Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
    Okamoto M; Okano A; Akamatsu S; Ashihara E; Inaba T; Takenaka H; Katoh N; Kishimoto S; Shimazaki C
    Leukemia; 2006 Jan; 20(1):172-3. PubMed ID: 16239908
    [No Abstract]   [Full Text] [Related]  

  • 37. Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases.
    Chosidow O; Bagot M; Vernant JP; Roujeau JC; Cordonnier C; Kuentz M; Wechsler J; André C; Touraine R; Revuz J
    J Am Acad Dermatol; 1992 Jan; 26(1):49-55. PubMed ID: 1732335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.
    Voltarelli JC; Ahmed H; Paton EJ; Stracieri AB; Holman P; Bashey A; Coutinho M; Simoes BP; Ball ED; Carrier E
    Bone Marrow Transplant; 2001 Jul; 28(1):97-9. PubMed ID: 11498752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presentations and treatment of childhood scleroderma: localized scleroderma, eosinophilic fasciitis, systemic sclerosis, and graft-versus-host disease.
    Hedrich CM; Fiebig B; Hahn G; Suttorp M; Gahr M
    Clin Pediatr (Phila); 2011 Jul; 50(7):604-14. PubMed ID: 21525084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dermatological complications of chronic graft versus host disease.
    Raina V; Shafi M; Bakar MA
    J Assoc Physicians India; 1985 Jul; 33(7):494-6. PubMed ID: 4055673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.